{"id":"drd2","name":"Dopamine D2 receptor","symbol":"DRD2","route":"/targets/drd2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3023","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149295","uniprot":"https://www.uniprot.org/uniprotkb/P14416/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P14416","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL217","open-targets":"https://platform.opentargets.org/target/ENSG00000149295","civic":"https://civicdb.org/genes/1813/summary","oncokb":"https://www.oncokb.org/gene/DRD2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DRD2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=DRD2","depmap":"https://depmap.org/portal/gene/DRD2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000149295-DRD2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1813","omim":"https://www.omim.org/entry/126450"}],"products":[{"id":"bromocriptine","name":"Bromocriptine","status":"approved","modality":"Oral ergot dopamine D2 receptor agonist","route":"/drugs/bromocriptine/"},{"id":"cabergoline","name":"Cabergoline","status":"approved","modality":"Oral long-acting dopamine D2 receptor agonist","route":"/drugs/cabergoline/"}],"trials":[{"id":"nct03271918","name":"Cabergoline in Nonfunctioning Pituitary Adenomas","nct":"NCT03271918","phase":"3","status":"completed"},{"id":"nct07463235","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","nct":"NCT07463235","phase":"3","status":"recruiting"},{"id":"nct00889525","name":"Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor","nct":"NCT00889525","phase":"3","status":"completed"}],"pathways":[],"companies":["novartis","pfizer"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}